LONDON, Aug 14 (Reuters) - Eli Lilly will raise the list price in the UK of its weight-loss and type 2 diabetes treatment Mounjaro by 170% to be in line with other European markets, the U.S. drugmaker said on Thursday. Lilly's Mounjaro launched in the UK in February last year, while rival Novo Nordisk's Wegovy treatment has been available in the country since September 2023. The new price is effective from September. Lilly said that the price for a month's supply of highest dose of the medicine will increase from $122 to £330, a 170% increase. In the UK, mirroring dynamics elsewhere, especially in the European markets, Lilly challenged Novo's first-mover advantage swiftly after launching. By late 2024, Mounjaro sales outstripped those of Wegovy in the booming online pharmacy market for the medicines, Reuters at the time. Lilly said in a statement that when it launched Mounjaro in Britain, it agreed to a list price 'significantly below' that in its three other European markets to prevent delays in availability of the medicine through Britain's National Health Service (NHS).

Eli Lilly to hike UK price of Mounjaro weight-loss, diabetes medicines by 170%

Eli Lilly announced a 170% price increase for its diabetes and weight-loss medication Mounjaro in the UK, raising the list price from $122 to £330 per month's supply of the highest dose. The new pricing is effective from September 2025 and aligns with prices in other European markets. The move follows the launch of Mounjaro in the UK in February 2024, where it initially offered a lower price than in other European regions to ensure timely NHS availability. Sales of Mounjaro have since surpassed those of Novo Nordisk's Wegovy in the UK's online pharmacy market by late 2024.